BETHESDA, Md. , Sept. 18, 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that it has appointed former pharmaceutical industry executive Dr. Gunter Rosskamp as the CEO of the Company's German subsidiary, Northwest Biotherapeutics, Gmbh.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO )

Dr. Rosskamp brings extensive experience as a senior manager in the pharmaceutical sector. He previously served as Head of Central Nervous System (CNS) therapeutics at Schering AG (now part of Bayer AG) with responsibility for research and development, and global marketing and sales, of CNS products. This included such drugs as Dopergin (for Parkinson's disease) and Noctamide (a sleeping aid).

Dr. Rosskamp also served as Project Leader for the development and registration (product approval) of the blockbuster drug, Betaseron (for multiple sclerosis), in the European Union.

He subsequently served as Head of Strategic Business Development at Schering AG reporting directly to the Board and determining suitable opportunities in existing franchise areas of the Company, such as hormone products and diagnostics, and new franchise areas such CNS therapeutics and cardiology.